Meta-analysis of venetoclax and hypomethylating agent therapy shows improved treatment outcomes in younger adults with AML, suggesting a shift in therapy approaches.
In this issue of Cancer , Perrone et al. present a metanalysis of published studies examining the use of venetoclax and hypomethylating agent therapy in younger adults with acute myeloid leukemia (AML). The authors synthesize a growing evidence base supporting the use of lower intensity regimens in younger adults, signaling a change to the treatment paradigm for AML.
No takes yet. Share an insight, caveat, or question.
Aubrey et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: